Insider Trading Alert - CNW, PPS And REGN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 5, 2014, 233 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.59 to $85,937,500.00.

Highlighted Stocks Traded by Insiders:

Con-way (CNW) - FREE Research Report

Dagnese Joseph M who is Executive Vice President at Con-way sold 1,379 shares at $39.23 on March 5, 2014. Following this transaction, the Executive Vice President owned 21,881 shares meaning that the stake was reduced by 5.93% with the 1,379-share transaction.

The shares most recently traded at $40.24, up $1.01, or 2.5% since the insider transaction. Historical insider transactions for Con-way go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares sold: 3,000

The average volume for Con-way has been 876,100 shares per day over the past 30 days. Con-way has a market cap of $2.2 billion and is part of the services sector and transportation industry. Shares are down 1.51% year-to-date as of the close of trading on Wednesday.

Con-way Inc., together with its subsidiaries, provides transportation, logistics, and supply chain management services to various manufacturing, industrial, and retail customers in North America and internationally. The stock currently has a dividend yield of 1.02%. The company has a P/E ratio of 22.6. Currently there are 5 analysts that rate Con-way a buy, 2 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNW - FREE

TheStreet Quant Ratings rates Con-way as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Con-way Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Post Properties (PPS) - FREE Research Report

Cohen Sherry W who is EVP and Secretary at Post Properties sold 10,000 shares at $49.89 on March 5, 2014. Following this transaction, the EVP and Secretary owned 20,461 shares meaning that the stake was reduced by 32.83% with the 10,000-share transaction.

Konas Charles A. who is Executive Vice Pres. at Post Properties sold 3,000 shares at $51.08 on March 5, 2014. Following this transaction, the Executive Vice Pres. owned 18,292 shares meaning that the stake was reduced by 14.09% with the 3,000-share transaction.

The shares most recently traded at $48.94, down $2.14, or 4.38% since the insider transaction. Historical insider transactions for Post Properties go as follows:

  • 4-Week # shares bought: 6,706
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 6,706
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 6,706
  • 24-Week # shares sold: 11,500

The average volume for Post Properties has been 585,700 shares per day over the past 30 days. Post Properties has a market cap of $2.7 billion and is part of the financial sector and real estate industry. Shares are up 9.48% year-to-date as of the close of trading on Wednesday.

Post Properties, Inc. is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It primarily develops, owns, and manages multi-family apartment communities. Post Properties, Inc. was founded in 1971 and is based in Atlanta, Georgia. The stock currently has a dividend yield of 2.91%. The company has a P/E ratio of 35.1. Currently there is 1 analyst that rates Post Properties a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PPS - FREE

TheStreet Quant Ratings rates Post Properties as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, compelling growth in net income, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Post Properties Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Sanofi who is 10% Owner at Regeneron Pharmaceuticals bought 251,594 shares at $338.12 on March 5, 2014. Following this transaction, the 10% Owner owned 17.0 million shares meaning that the stake was reduced by 1.5% with the 251,594-share transaction.

The shares most recently traded at $348.01, up $9.89, or 2.84% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 16,000
  • 24-Week # shares sold: 17,000

The average volume for Regeneron Pharmaceuticals has been 969,700 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $33.8 billion and is part of the health care sector and drugs industry. Shares are up 25.57% year-to-date as of the close of trading on Wednesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 90.7. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Jim Cramer -- Transports Are the Ugliest Part of the Market Right Now

Jim Cramer -- Transports Are the Ugliest Part of the Market Right Now

Knight Transportation to Accelerate Buying as Trucking Hits Brakes

Knight Transportation to Accelerate Buying as Trucking Hits Brakes

As the Trucking Industry Slows, Knight Likely to Accelerate

As the Trucking Industry Slows, Knight Likely to Accelerate

American Airlines (AAL) Stock Prepared for Takeoff

American Airlines (AAL) Stock Prepared for Takeoff

Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate

Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate